| Budget Amount *help |
¥104,650,000 (Direct Cost: ¥80,500,000、Indirect Cost: ¥24,150,000)
Fiscal Year 2021: ¥19,500,000 (Direct Cost: ¥15,000,000、Indirect Cost: ¥4,500,000)
Fiscal Year 2020: ¥19,500,000 (Direct Cost: ¥15,000,000、Indirect Cost: ¥4,500,000)
Fiscal Year 2019: ¥19,500,000 (Direct Cost: ¥15,000,000、Indirect Cost: ¥4,500,000)
Fiscal Year 2018: ¥19,500,000 (Direct Cost: ¥15,000,000、Indirect Cost: ¥4,500,000)
Fiscal Year 2017: ¥26,650,000 (Direct Cost: ¥20,500,000、Indirect Cost: ¥6,150,000)
|
|---|
| Outline of Final Research Achievements |
Brain tumors are difficult to treat, and there are some genetic mutations which associated with prognosis. In this study, we focused on single nucleotide polymorphism (SNP) and aimed at rapid intraoperative genetic diagnosis of brain tumors, and preoperative non-invasive genetic diagnosis in a short time from patient`s urine. The SNPs analysis system detects mutations by binding a specific probe to the gene mutation site, denatures the binding by heating and emits light. It takes only 60 minutes to rapid intraoperative diagnosis. Nanowire device can capture trace tumor-derived nucleic acids in urine. In this study, we developed probes for IDH2, EGFR, BRAF, H3F3A gene mutations. We also constructed a highly sensitive measurement system for the IDH1 R132H mutation and succeeded in detecting 0.01% mutation.
|
